Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible?

This publication has 75 references indexed in Scilit:

• Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics
  Proceedings of the National Academy of Sciences, 2007
• A viral microRNA functions as an orthologue of cellular miR-155
  Nature, 2007
• miR-122 targeting with LNA/2′-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA–peptide conjugates
  RNA, 2007
• Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications
  RNA, 2007
• The Bcl-2 apoptotic switch in cancer development and therapy
  Oncogene, 2007
• First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology
  Circulation, 2006
• A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers
  Investigational New Drugs, 2005
• Antisense oligonucleotide-based therapeutics for cancer
  Oncogene, 2003
• Fomivirsen
  Drugs, 1999
• Large‐Scale Economic Synthesis of Antisense Phosphorothioate Analogues of DNA for Preclinical Investigations
  Annals of the New York Academy of Sciences, 1990